Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company's segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals. The Company enables plasma collection customers to source from it a range of products necessary for plasma collection and storage, including PCS brand plasma collection equipment and disposables, plasma collection containers and intravenous solutions, such as saline. Haemonetics offers automated blood component and manual whole blood collection systems to blood collection centers to collect blood products. The Company offers a range of blood management solutions. The Company has a suite of integrated software solutions, which include solutions for blood drive planning and blood collection.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Equipment, Supplies & Distribution - NEC
- Sub-Industry: Health Care Supplies
- Symbol: NYSE:HAE
- CUSIP: 40502410
- Web: www.haemonetics.com
Capitalization:- Market Cap: $2.08907 billion
- Outstanding Shares: 52,464,000
Average Prices:- 50 Day Moving Avg: $40.13
- 200 Day Moving Avg: $40.04
- 52 Week Range: $29.17 - $43.62
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 23.51
- P/E Growth: 3.24
Sales & Book Value:- Annual Revenue: $886.12 million
- Price / Sales: 2.37
- Book Value: $14.15 per share
- Price / Book: 2.82
Profitability:- EBIDTA: $139.74 million
- Net Margins: -2.96%
- Return on Equity: 10.66%
- Return on Assets: 6.10%
Debt:- Debt-to-Equity Ratio: 0.34%
- Current Ratio: 2.42%
- Quick Ratio: 1.58%
Misc:- Average Volume: 314,614 shs.
- Beta: 0.89
- Short Ratio: 9.35
Frequently Asked Questions for Haemonetics Corporation (NYSE:HAE)
What is Haemonetics Corporation's stock symbol?
Haemonetics Corporation trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."
How were Haemonetics Corporation's earnings last quarter?
Haemonetics Corporation (NYSE:HAE) issued its quarterly earnings results on Monday, May, 8th. The company reported $0.39 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.37 by $0.02. The business had revenue of $228.10 million for the quarter, compared to the consensus estimate of $215.06 million. Haemonetics Corporation had a negative net margin of 2.96% and a positive return on equity of 10.66%. The firm's quarterly revenue was down 5.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.37 EPS. View Haemonetics Corporation's Earnings History.
What guidance has Haemonetics Corporation issued on next quarter's earnings?
Haemonetics Corporation issued an update on its FY18 earnings guidance on Monday, May, 8th. The company provided earnings per share (EPS) guidance of $1.55-1.65 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.59. The company issued revenue guidance of to approximate FY17 of $886.1 million, compared to the consensus revenue estimate of $899.98 million.
Where is Haemonetics Corporation's stock going? Where will Haemonetics Corporation's stock price be in 2017?
8 brokers have issued 12 month price targets for Haemonetics Corporation's shares. Their forecasts range from $24.00 to $50.00. On average, they expect Haemonetics Corporation's share price to reach $37.86 in the next year. View Analyst Ratings for Haemonetics Corporation.
Who are some of Haemonetics Corporation's key competitors?
Some companies that are related to Haemonetics Corporation include Integra LifeSciences Holdings Corporation (IART), NuVasive (NUVA), ICU Medical (ICUI), LivaNova PLC (LIVN), Neogen Corporation (NEOG), Nevro Corp. (NVRO), Inogen (INGN), Halyard Health (HYH), MiMedx Group (MDXG), CONMED Corporation (CNMD), K2M Group Holdings (KTWO), Cardiovascular Systems (CSII), OraSure Technologies (OSUR), Asante Solutions (PUMP), Orthofix International N.V. (OFIX), AtriCure (ATRC), Intersect ENT (XENT) and Meridian Bioscience (VIVO).
Who are Haemonetics Corporation's key executives?
Haemonetics Corporation's management team includes the folowing people:
- Christopher Simon, President, Chief Executive Officer, Director
- William P. Burke, Chief Financial Officer, Executive Vice President
- Michelle Basil, Executive Vice President, General Counsel
- Neil Ryding, Executive Vice President, Global Operations
- Richard J. Meelia, Non-Executive Independent Chairman of the Board
- Catherine M. Burzik, Independent Director
- Charles J. Dockendorff, Independent Director
- Susan Bartlett Foote, Independent Director
- Ronald G. Gelbman, Independent Director
Who owns Haemonetics Corporation stock?
Haemonetics Corporation's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Van Berkom & Associates Inc. (2.30%), Hermes Investment Management Ltd. (1.31%), BTIM Corp. (0.57%), Fisher Asset Management LLC (0.46%), Confluence Investment Management LLC (0.10%) and US Bancorp DE (0.04%). Company insiders that own Haemonetics Corporation stock include Brian Concannon, Byron Selman, Christopher J Lindop, Christopher Simon, Ronald G Gelbman, Ronald Merriman, Sandra Jesse and Susan M Hanlon. View Institutional Ownership Trends for Haemonetics Corporation.
Who sold Haemonetics Corporation stock? Who is selling Haemonetics Corporation stock?
Haemonetics Corporation's stock was sold by a variety of institutional investors in the last quarter, including BTIM Corp., Hermes Investment Management Ltd., First Quadrant L P CA, Capstone Asset Management Co., Confluence Investment Management LLC and Fisher Asset Management LLC. Company insiders that have sold Haemonetics Corporation stock in the last year include Ronald G Gelbman and Ronald Merriman. View Insider Buying and Selling for Haemonetics Corporation.
Who bought Haemonetics Corporation stock? Who is buying Haemonetics Corporation stock?
Haemonetics Corporation's stock was bought by a variety of institutional investors in the last quarter, including Van Berkom & Associates Inc., Legato Capital Management LLC, Fox Run Management L.L.C., Eqis Capital Management Inc., State of Alaska Department of Revenue, Kirr Marbach & Co. LLC IN, Aperio Group LLC and Louisiana State Employees Retirement System. View Insider Buying and Selling for Haemonetics Corporation.
How do I buy Haemonetics Corporation stock?
Shares of Haemonetics Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Haemonetics Corporation's stock price today?
One share of Haemonetics Corporation stock can currently be purchased for approximately $39.96.
MarketBeat Community Rating for Haemonetics Corporation (NYSE HAE)MarketBeat's community ratings are surveys of what our community members think about Haemonetics Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Haemonetics Corporation (NYSE:HAE) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Sell Rating, 5 Hold Ratings, 2 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.13) |
| Consensus Price Target: | $37.86 (5.26% downside) |
Analysts' Ratings History for Haemonetics Corporation (NYSE:HAE)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/13/2017 | JMP Securities | Upgrade | Market Perform -> Outperform | $50.00 | High |  |
| 5/8/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $42.00 | Medium | |
| 2/7/2017 | Barrington Research | Downgrade | Outperform -> Market Perform | | N/A | |
| 11/7/2016 | BTIG Research | Reiterated Rating | Neutral | | N/A | |
| 11/7/2016 | Benchmark Co. | Boost Price Target | Hold | $32.00 -> $34.00 | N/A | |
| 10/14/2016 | Off Wall Street | Initiated Coverage | Sell | $24.00 | N/A | |
| 9/20/2016 | CJS Securities | Downgrade | Market Outperform -> Market Perform | $35.00 | N/A | |
| 8/15/2016 | Sidoti | Downgrade | Buy -> Neutral | $39.00 | N/A | |
| 5/16/2016 | Goldman Sachs Group, Inc. (The) | Upgrade | Sell -> Neutral | $29.00 | N/A | |
| 5/12/2016 | Morgan Stanley | Reiterated Rating | Hold | | N/A | |
| 2/2/2016 | William Blair | Reiterated Rating | Market Perform | | N/A | |
| 11/23/2015 | Raymond James Financial, Inc. | Downgrade | Market Perform -> Underperform | | N/A | |
(Data available from 7/25/2015 forward)
Earnings History for Haemonetics Corporation (NYSE:HAE)Earnings History by Quarter for Haemonetics Corporation (NYSE HAE)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/8/2017 | Q4 2017 | $0.37 | $0.39 | $215.06 million | $228.10 million | View | Listen | |
| 2/6/2017 | Q317 | $0.40 | $0.43 | $220.00 million | $227.80 million | View | Listen | |
| 11/7/2016 | Q217 | $0.35 | $0.46 | $210.72 million | $220.30 million | View | Listen | |
| 8/1/2016 | Q117 | $0.28 | $0.25 | $205.41 million | $210.00 million | View | Listen | |
| 5/2/2016 | Q416 | $0.46 | $0.37 | $245.08 million | $243.20 million | View | Listen | |
| 2/1/2016 | Q316 | $0.46 | $0.48 | $237.37 million | $233.40 million | View | Listen | |
| 11/4/2015 | Q216 | $0.40 | $0.44 | $226.50 million | $219.70 million | View | Listen | |
| 7/27/2015 | Q116 | $0.33 | $0.35 | $215.62 million | $213.40 million | View | Listen | |
| 4/27/2015 | Q415 | $0.51 | $0.47 | $239.20 million | $226.50 million | View | Listen | |
| 1/29/2015 | Q315 | $0.51 | $0.53 | $235.45 million | $231.80 million | View | Listen | |
| 11/3/2014 | Q215 | $0.45 | $0.47 | $229.90 million | $227.60 million | View | Listen | |
| 7/30/2014 | Q115 | $0.35 | $0.38 | $215.85 million | $224.49 million | View | Listen | |
| 4/28/2014 | Q414 | $0.58 | $0.46 | $244.87 million | $241.00 million | View | Listen | |
| 1/27/2014 | Q314 | $0.61 | $0.61 | $243.71 million | $242.10 million | View | Listen | |
| 10/28/2013 | Q214 | $0.57 | $0.66 | $239.51 million | $235.80 million | View | Listen | |
| 7/29/2013 | Q1 2014 | $0.47 | $0.46 | $232.98 million | $219.50 million | View | Listen | |
| 5/1/2013 | Q4 2013 | $0.46 | $0.48 | $249.33 million | $249.90 million | View | Listen | |
| 1/30/2013 | Q3 2013 | $0.47 | $0.50 | $251.93 million | $247.40 million | View | Listen | |
| 10/29/2012 | Q213 | $0.77 | $0.90 | $223.47 million | $218.18 million | View | N/A | |
| 8/1/2012 | | $0.71 | $0.55 | | | View | N/A | |
| 4/30/2012 | | $0.83 | $0.80 | | | View | N/A | |
| 1/30/2012 | | $0.80 | $0.86 | | | View | N/A | |
| 10/31/2011 | | $0.77 | $0.72 | | | View | N/A | |
| 8/1/2011 | | $0.77 | $0.65 | | | View | N/A | |
| 5/2/2011 | | $0.83 | $0.85 | | | View | N/A | |
| 1/31/2011 | | $0.82 | $0.89 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Haemonetics Corporation (NYSE:HAE)2017 EPS Consensus Estimate: $1.35
2018 EPS Consensus Estimate: $1.58
2019 EPS Consensus Estimate: $1.59
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 3 | $0.26 | $0.30 | $0.27 |
| Q2 2017 | 3 | $0.29 | $0.34 | $0.32 |
| Q3 2017 | 3 | $0.37 | $0.42 | $0.39 |
| Q4 2017 | 3 | $0.35 | $0.38 | $0.36 |
| Q1 2018 | 3 | $0.25 | $0.37 | $0.30 |
| Q2 2018 | 3 | $0.38 | $0.47 | $0.44 |
| Q3 2018 | 3 | $0.43 | $0.47 | $0.44 |
| Q4 2018 | 2 | $0.39 | $0.41 | $0.40 |
| Q1 2019 | 1 | $0.25 | $0.25 | $0.25 |
| Q2 2019 | 1 | $0.45 | $0.45 | $0.45 |
| Q3 2019 | 1 | $0.47 | $0.47 | $0.47 |
| Q4 2019 | 1 | $0.42 | $0.42 | $0.42 |
(Data provided by Zacks Investment Research)
Dividend History for Haemonetics Corporation (NYSE:HAE)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Haemonetics Corporation (NYSE:HAE)Insider Ownership Percentage: 1.20%
Insider Trades by Quarter for Haemonetics Corporation (NYSE:HAE)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/22/2017 | Ronald Merriman | Director | Sell | 17,471 | $40.33 | $704,605.43 | |
| 12/12/2016 | Ronald G Gelbman | Director | Sell | 5,683 | $40.30 | $229,024.90 | |
| 8/17/2016 | Ronald Merriman | Director | Sell | 4,337 | $35.14 | $152,402.18 | |
| 8/4/2016 | Christopher Simon | CEO | Buy | 60,000 | $35.00 | $2,100,000.00 | |
| 10/26/2015 | Byron Selman | Insider | Sell | 344 | $32.13 | $11,052.72 | |
| 10/26/2015 | Christopher J Lindop | CFO | Sell | 436 | $32.13 | $14,008.68 | |
| 10/26/2015 | Sandra Jesse | EVP | Sell | 778 | $32.13 | $24,997.14 | |
| 10/26/2015 | Susan M Hanlon | VP | Sell | 497 | $32.13 | $15,968.61 | |
| 9/15/2015 | Brian Concannon | CEO | Sell | 6,569 | $35.15 | $230,900.35 | |
| 9/1/2015 | Brian Concannon | CEO | Sell | 4,765 | $35.63 | $169,776.95 | |
| 8/20/2015 | Christopher J. Lindop | CFO | Sell | 4,902 | $38.49 | $188,677.98 | |
| 8/17/2015 | Brian Concannon | CEO | Sell | 6,569 | $39.28 | $258,030.32 | |
| 7/20/2015 | Christopher J Lindop | CFO | Sell | 4,902 | $39.09 | $191,619.18 | |
| 7/15/2015 | Brian Concannon | CEO | Sell | 6,569 | $39.59 | $260,066.71 | |
| 7/6/2015 | Peter M Allen | Insider | Sell | 30,494 | $40.19 | $1,225,553.86 | |
| 7/2/2015 | Jonathan White | Insider | Sell | 2,385 | $41.14 | $98,118.90 | |
| 6/22/2015 | Christopher J Lindop | CFO | Sell | 4,902 | $42.51 | $208,384.02 | |
| 6/15/2015 | Brian Concannon | CEO | Sell | 6,569 | $42.51 | $279,248.19 | |
| 6/10/2015 | Susan M Hanlon | VP | Sell | 6,000 | $43.00 | $258,000.00 | |
| 6/1/2015 | Brian Concannon | CEO | Sell | 4,765 | $41.39 | $197,223.35 | |
| 5/20/2015 | Christopher J Lindop | CFO | Sell | 4,902 | $41.65 | $204,168.30 | |
| 5/1/2015 | Brian Concannon | CEO | Sell | 4,765 | $40.74 | $194,126.10 | |
| 4/20/2015 | Christopher J Lindop | CFO | Sell | 4,902 | $41.55 | $203,678.10 | |
| 4/1/2015 | Brian Concannon | CEO | Sell | 4,765 | $44.51 | $212,090.15 | |
| 3/27/2015 | Susan M Hanlon | VP | Sell | 7,000 | $43.46 | $304,220.00 | |
| 3/20/2015 | Christopher J Lindop | CFO | Sell | 4,902 | $44.26 | $216,962.52 | |
| 3/10/2015 | Susan Bartlett Foote | Director | Sell | 11,328 | $43.84 | $496,619.52 | |
| 3/5/2015 | Ronald G Gelbman | Director | Sell | 7,707 | $44.76 | $344,965.32 | |
| 3/4/2015 | Ronald Merriman | Director | Sell | 14,258 | $43.80 | $624,500.40 | |
| 3/2/2015 | Brian Concannon | CEO | Sell | 4,765 | $44.41 | $211,613.65 | |
| 2/18/2015 | Pedro P Granadillo | Director | Sell | 11,328 | $43.45 | $492,201.60 | |
| 2/2/2015 | Brian Concannon | CEO | Sell | 4,765 | $39.15 | $186,549.75 | |
| 1/2/2015 | Brian Concannon | CEO | Sell | 4,765 | $37.20 | $177,258.00 | |
| 12/1/2014 | Brian Concannon | CEO | Sell | 4,765 | $36.72 | $174,970.80 | |
| 11/3/2014 | Brian Concannon | CEO | Sell | 4,765 | $35.86 | $170,872.90 | |
| 10/13/2014 | Peter M Allen | Insider | Sell | 36,426 | $35.22 | $1,282,923.72 | |
| 8/12/2014 | Ronald Merriman | Director | Sell | 13,602 | $35.76 | $486,407.52 | |
| 8/1/2014 | Brian Concannon | CEO | Sell | 4,380 | $35.27 | $154,482.60 | |
| 7/7/2014 | Pedro P Granadillo | Director | Sell | 5,837 | $35.97 | $209,956.89 | |
| 6/12/2014 | Ronald G Gelbman | Director | Sell | 9,184 | $34.00 | $312,256.00 | |
| 6/6/2014 | Pedro P Granadillo | Director | Sell | 5,837 | $34.69 | $202,485.53 | |
| 5/12/2014 | Susan Bartlett Foote | Director | Sell | 9,184 | $33.16 | $304,541.44 | |
| 5/7/2014 | Pedro Granadillo | Director | Sell | 5,837 | $31.14 | $181,764.18 | |
| 5/1/2014 | Brian Concannon | CEO | Sell | 4,600 | $30.01 | $138,046.00 | |
| 4/28/2014 | Peter Allen | Insider | Sell | 30,000 | $30.70 | $921,000.00 | |
| 4/7/2014 | Pedro Granadillo | Director | Sell | 5,837 | $31.98 | $186,667.26 | |
| 4/1/2014 | Brian Concannon | CEO | Sell | 4,600 | $32.71 | $150,466.00 | |
| 3/6/2014 | Ronald Gelbman | Director | Sell | 12,000 | $36.17 | $434,040.00 | |
| 3/3/2014 | Brian Concannon | CEO | Sell | 4,600 | $36.36 | $167,256.00 | |
| 2/18/2014 | Susan Hanlon | VP | Sell | 3,690 | $39.00 | $143,910.00 | |
| 2/7/2014 | Jonathan White | Insider | Sell | 1,880 | $38.66 | $72,680.80 | |
| 2/3/2014 | Brian Concannon | CEO | Sell | 7,600 | $37.63 | $285,988.00 | |
| 1/27/2014 | Susan Hanlon | VP | Sell | 3,206 | $38.37 | $123,014.22 | |
| 1/10/2014 | Susan Hanlon | VP | Sell | 4,000 | $41.80 | $167,200.00 | |
| 1/2/2014 | Brian Concannon | CEO | Sell | 7,600 | $41.58 | $316,008.00 | |
| 12/16/2013 | Susan Hanlon | VP | Sell | 4,000 | $43.50 | $174,000.00 | |
| 12/9/2013 | Susan Hanlon | VP | Sell | 3,138 | $43.07 | $135,153.66 | |
| 12/2/2013 | Brian Concannon | CEO | Sell | 7,600 | $42.31 | $321,556.00 | |
| 11/12/2013 | Michael Kelly | Insider | Sell | 61,400 | $39.70 | $2,437,580.00 | |
| 11/1/2013 | Brian Concannon | CEO | Sell | 7,600 | $39.96 | $303,696.00 | |
| 10/14/2013 | Michael Kelly | Insider | Sell | 1,400 | $40.41 | $56,574.00 | |
| 9/13/2013 | Michael Kelly | Insider | Sell | 1,400 | $40.36 | $56,504.00 | |
| 9/3/2013 | Brian Concannon | CEO | Sell | 13,000 | $39.87 | $518,310.00 | |
| 8/1/2013 | Brian Concannon | CEO | Sell | 13,000 | $42.24 | $549,120.00 | |
| 7/12/2013 | Michael P Kelly | Insider | Sell | 1,400 | $44.10 | $61,740.00 | |
| 7/1/2013 | Brian Concannon | CEO | Sell | 13,000 | $41.87 | $544,310.00 | |
| 6/18/2013 | Christopher J Lindop | CFO | Sell | 68,628 | $42.50 | $2,916,690.00 | |
| 6/14/2013 | Michael P Kelly | Insider | Sell | 1,400 | $42.17 | $59,038.00 | |
| 6/3/2013 | Brian Concannon | CEO | Sell | 13,000 | $41.15 | $534,950.00 | |
| 5/21/2013 | Christopher J Lindop | CFO | Sell | 42,882 | $42.00 | $1,801,044.00 | |
| 5/14/2013 | Michael P Kelly | Insider | Sell | 1,400 | $39.66 | $55,524.00 | |
| 5/1/2013 | Brian Concannon | CEO | Sell | 13,000 | $38.66 | $502,580.00 | |
| 12/3/2012 | Brian Concannon | CEO | Sell | 13,000 | $40.75 | $529,750.00 | |
| 11/12/2012 | Pedro P Granadillo | Director | Sell | 16,000 | $80.40 | $1,286,400.00 | |
| 9/4/2012 | Brian Concannon | CEO | Sell | 6,500 | $73.68 | $478,920.00 | |
| 9/4/2012 | Christopher J Lindop | CFO | Sell | 61,783 | $74.34 | $4,592,948.22 | |
(Data available from 1/1/2013 forward)
Headline Trends for Haemonetics Corporation (NYSE:HAE)
Latest Headlines for Haemonetics Corporation (NYSE:HAE)
| Source: |
|
| Date | Headline |
|---|
 | Haemonetics Corp. breached its 50 day moving average in a Bearish Manner : HAE-US : July 24, 2017
finance.yahoo.com - July 24 at 10:00 PM |
| Haemonetics Sets Date for Publishing 1st Quarter Fiscal 2018 Results: August 7, 2017
finance.yahoo.com - July 18 at 9:17 PM |
 | Haemonetics Corporation (HAE) Rating Increased to Outperform at JMP Securities
www.americanbankingnews.com - July 16 at 7:02 PM |
| Haemonetics Corporation (NYSE:HAE) Expected to Post Quarterly Sales of $213.55 Million
www.americanbankingnews.com - July 14 at 2:06 PM |
| Believe In The Haemonetics Turnaround Story; JMP Upgrades To Market Outperform
finance.yahoo.com - July 13 at 8:59 PM |
| Haemonetics Co. (HAE) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - July 12 at 8:26 PM |
| Brokerages Anticipate Haemonetics Corporation (HAE) to Announce $0.31 Earnings Per Share
www.americanbankingnews.com - July 12 at 12:56 PM |
| Haemonetics Corporation (HAE) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - July 11 at 12:40 AM |
| ETFs with exposure to Haemonetics Corp. : July 6, 2017
finance.yahoo.com - July 7 at 5:58 AM |
| Haemonetics Corporation (HAE) Lowered to Sell at BidaskClub
www.americanbankingnews.com - June 23 at 9:00 PM |
| Haemonetics Announces Formation of Scientific Advisory Council
finance.yahoo.com - June 23 at 2:58 AM |
| Brokerages Anticipate Haemonetics Corporation (HAE) Will Announce Quarterly Sales of $213.55 Million
www.americanbankingnews.com - June 18 at 9:42 AM |
| Haemonetics Corporation (HAE) Expected to Post Earnings of $0.31 Per Share
www.americanbankingnews.com - June 16 at 12:32 PM |
| Haemonetics Will Webcast Investor and Analyst Meeting
finance.yahoo.com - June 14 at 7:06 PM |
| Haemonetics Rides on Solid Plasma, Slows Blood Center Growth
finance.yahoo.com - June 14 at 7:06 PM |
| Haemonetics Corp. :HAE-US: Earnings Analysis: Q4, 2017 By the Numbers : June 14, 2017
finance.yahoo.com - June 14 at 11:50 AM |
| Haemonetics Corporation (HAE) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - June 14 at 12:46 AM |
| ETFs with exposure to Haemonetics Corp. : June 13, 2017
finance.yahoo.com - June 13 at 5:24 PM |
| Haemonetics (HAE) Down 2.2% Since Earnings Report: Can It Rebound?
finance.yahoo.com - June 13 at 11:08 AM |
| Haemonetics Corp. breached its 50 day moving average in a Bearish Manner : HAE-US : June 13, 2017
finance.yahoo.com - June 13 at 11:08 AM |
| ETFs with exposure to Haemonetics Corp. : May 30, 2017
finance.yahoo.com - May 30 at 5:30 PM |
| Haemonetics Corp. breached its 50 day moving average in a Bullish Manner : HAE-US : May 29, 2017
finance.yahoo.com - May 29 at 9:56 AM |
| Haemonetics Corp. :HAE-US: Earnings Analysis: 2017 By the Numbers : May 26, 2017
finance.yahoo.com - May 26 at 6:17 PM |
| Haemonetics Corp (HAE) Files 10-K for the Fiscal Year Ended on March 31, 2017
finance.yahoo.com - May 25 at 3:47 AM |
| Haemonetics Co. (HAE) Director Sells $704,605.43 in Stock
www.americanbankingnews.com - May 24 at 10:35 PM |
 | Apheresis Equipment Market is expected to reach USD 3.7 billion by 2024
www.bizjournals.com - May 23 at 11:36 AM |
| Haemonetics Sets Date for Investor / Analyst Meeting - June 19, 2017
finance.yahoo.com - May 22 at 5:10 PM |
| Haemonetics Co. (HAE) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - May 20 at 12:12 AM |
| Haemonetics Corp. – Value Analysis (NYSE:HAE) : May 19, 2017
finance.yahoo.com - May 19 at 5:21 PM |
| Haemonetics Corp. breached its 50 day moving average in a Bearish Manner : HAE-US : May 18, 2017
finance.yahoo.com - May 18 at 9:45 AM |
| TheStreet Lowers Haemonetics Co. (HAE) to C
www.americanbankingnews.com - May 13 at 3:58 PM |
| Haemonetics Co. (HAE) Expected to Earn Q1 2019 Earnings of $0.25 Per Share
www.americanbankingnews.com - May 11 at 3:20 PM |
| Equities Analysts Set Expectations for Haemonetics Co.'s FY2018 Earnings (HAE)
www.americanbankingnews.com - May 11 at 2:36 PM |
| FY2018 Earnings Forecast for Haemonetics Co. (HAE) Issued By Jefferies Group
www.americanbankingnews.com - May 11 at 2:36 PM |
| Haemonetics Co. (HAE) Expected to Earn FY2018 Earnings of $1.59 Per Share
www.americanbankingnews.com - May 10 at 2:32 PM |
| Haemonetics Co. (HAE) to Post Q1 2018 Earnings of $0.27 Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - May 10 at 1:08 PM |
| Barrington Research Equities Analysts Boost Earnings Estimates for Haemonetics Co. (HAE)
www.americanbankingnews.com - May 10 at 1:08 PM |
| Brokers Offer Predictions for Haemonetics Co.'s Q1 2018 Earnings (HAE)
www.americanbankingnews.com - May 10 at 1:08 PM |
| Edited Transcript of HAE earnings conference call or presentation 8-May-17 12:00pm GMT
finance.yahoo.com - May 10 at 12:35 PM |
| Haemonetics Co. (HAE) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - May 9 at 5:02 PM |
| Haemonetics Co. (HAE) Stock Rating Reaffirmed by Jefferies Group LLC
www.americanbankingnews.com - May 8 at 10:16 PM |
| Haemonetics Co. (HAE) Announces Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - May 8 at 8:56 PM |
 | Haemonetics (HAE) Q4 2017 Results - Earnings Call Transcript
seekingalpha.com - May 8 at 5:19 PM |
| Haemonetics Co. (HAE) Issues FY18 Earnings Guidance
www.americanbankingnews.com - May 8 at 11:38 AM |
| Haemonetics 4th Quarter and Fiscal Year 2017 Earnings Release and Fiscal Year 2018 Guidance Available on Investor Relations Website
finance.yahoo.com - May 8 at 8:15 AM |
| Haemonetics reports 4Q loss
finance.yahoo.com - May 8 at 8:15 AM |
| Haemonetics beats by $0.01, beats on revenue
seekingalpha.com - May 8 at 6:25 AM |
| Somewhat Favorable News Coverage Likely to Affect Haemonetics (HAE) Share Price
www.americanbankingnews.com - May 4 at 8:22 PM |
| Somewhat Critical Press Coverage Very Likely to Affect Haemonetics (HAE) Share Price
www.americanbankingnews.com - May 1 at 3:42 PM |
| Haemonetics Co. (HAE) Expected to Announce Quarterly Sales of $221.08 Million
www.americanbankingnews.com - April 30 at 9:12 AM |
Haemonetics Corporation (HAE) Chart for Tuesday, July, 25, 2017
